NVS - Novartis AG
| Previous Close | 95.10 |
| Open | 95.72 |
| Bid | 95.45 x 800 |
| Ask | 96.83 x 1800 |
| Day's Range | 95.40 - 96.06 |
| 52 Week Range | 74.97 - 96.06 |
| Volume | 1,845,186 |
| Avg. Volume | 1,566,601 |
| Market Cap | 217.182B |
| Beta (5Y Monthly) | 0.51 |
| PE Ratio (TTM) | 18.93 |
| EPS (TTM) | 5.07 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.83 (2.98%) |
| Ex-Dividend Date | Mar 02, 2019 |
| 1y Target Est | 101.00 |
- Zacks
Will J&J (JNJ) Roll Out Pharma Q4 Earnings With a Beat?
J&J's (JNJ) cancer drugs are expected to have contributed significantly to fourth-quarter 2019 earnings. Generic/biosimilar headwinds are expected to have hurt Pharma unit's sales.
- Zacks
Pharma Stock Roundup: LLY Dermira Buyout Offer, Pipeline & Regulatory Updates
Lilly (LLY) offers to buy Dermira for $1.1 billion. AstraZeneca (AZN) and AbbVie (ABBV) provide pipeline updates.
- Financial Times
Gene therapies test Europe’s willingness to pay
The drive to cure deadly diseases is about to enter a new and demanding phase as the pharmaceutical industry prepares for the first time to test the appetite for hyper-expensive gene therapies in Europe. The willingness of traditionally cash-strapped European health systems to pay for these innovative treatments will affect future investment in the field. , a treatment for rare blood disorder Beta thalassaemia that is manufactured by Bluebird Bio.
- Reuters
Novartis to speed access to $10 billion heart drug via NHS deal
Novartis and Britain's National Health Service (NHS) on Monday announced a pact that will clear the way for accelerated review by the country's health watchdog NICE for heart drug inclisiran, which could make it broadly available as soon as 2021. Novartis hopes the NHS deal will boost sales of cholesterol-lowering inclisiran, which the Swiss drugmaker bought in a deal announced last year for nearly $10 billion (£7.70 billion) and predicts will be a top seller. Inclisiran was submitted to U.S. regulators last year, and Novartis expects a European submission in coming weeks.
- Zacks
Alnylam Provides Preliminary Q4 Sales for Onpattro & Givlaari
Alnylam (ALNY) announces preliminary results for the fourth quarter and 2019 and provides other updates.
- TheStreet.com
Novartis, U.K. National Health Service Partner for Trial of Cholesterol-Drug Candidate
Novartis and the U.K. health agency will conduct a trial, with as many as 40,000 patients, of the Basel drug giant's cholesterol-lowering candidate inclisiran.
- Financial Times
UK’s NHS teams with Novartis to launch heart attack drug trial
Britons at risk of heart attacks are set to receive a twice-yearly injection in a bid to save up to 30,000 lives over a decade, under one of the biggest population-wide prevention initiatives undertaken anywhere in the world. Inclisiran, a cholesterol-lowering medicine, will first be tested in a large UK clinical trial that will make use of the extensive National Health Service data base to identify and track suitable patients. Assuming the trial is successful, the drug will be made available across the English health service.
- Zacks
Regeneron's Phase II Candidate Promising in Primary Analysis
Regeneron (REGN) announces encouraging results from the phase II study on rare bone disease candidate.
- InvestorPlace
3 Biotech Stocks to Bank on for Buyouts in 2020
Heading into the new year, only one word matters for the biotech stocks: buyout.Already, we've seen a fury of activity this past year, as many of the larger pharmaceutical and biotech giants look to plug holes in their aging pipelines. This activity accelerated at the end of the end, with Novartis (NYSE:NVS), Merck (NYSE:MRK) and Sanofi (NASDAQ:SNY) all making big blockbuster buys over the last month or so.And, the buys could continue into the new year.InvestorPlace - Stock Market News, Stock Advice & Trading TipsFor one thing, many of the big biotech stocks are flushed with cash. Thanks to the tax cuts of 2017, repatriation of cash and continued sales of blockbuster drugs, many of the biggest biotech stocks are holding billions on their balance sheets. Meanwhile, pipelines and approvals of new drugs are starting to dry up. According to investment bank JPMorgan Chase (NYSE:JPM), over the last 20 years, the FDA has only approved an average of between 20 and 25 new drugs per year. Most of those approvals have come from advanced drugs, new cancer fighters and a hefty dose of biologics.With the need to fill pipelines and replace aging blockbusters, the major biotech stocks are in a bind. And that means buying their way out of these issues. * The Top 15 Stocks to Buy in 2020 For investors, this poises an interesting scenario. Plenty of gains can be had betting on the right biotech stock with a promising pipeline as the bigger fish start spending their cash. However, which biotech stocks have the promise?Here are three biotech stocks that make for great buyout targets. Biotech Stocks That Are Buyout Targets: Arrowhead Pharmaceuticals (ARWR)Source: Shutterstock It's no secret that gene therapy has quickly become all the rage, with pharmaceutical firms trying to tackle rare and orphan diseases. And while there are a ton of new technologies that fall under this umbrella, RNA interference (RNAi) has the potential to be a real game changer.Basically, it's a mechanism that uses a "gene's own DNA sequence of gene to turn it off." With Novartis spending nearly $10 billion on RNAi buyouts in recent months, Arrowhead Pharmaceuticals (NASDAQ:ARWR) could be an intriguing stock to look at it.ARWR's sole specialty is RNAi drugs and features a big pipeline of therapies in various stages of development. These drugs include tackling aliments like liver disease, Cystic Fibrosis and cancerous tumors. So far, the biotech has been pretty successful at navigating the various phases of clinical trials. Data from many of its late-stage drugs seem very promising.However, the real reason to be excited that ARWR could be bought out is that it already counts a very deep-pocketed biotech among its development partners. Arrowhead has already cut deals with Johnson & Johnson (NYSE:JNJ) for development of treatment for chronic hepatitis B infections. The deal provides ARWR with plenty of upfront cash, development and milestone rights. However, given the rush to buyout RNAi providers, JNJ has every reason to consider snagging the firm outright.Now, Arrowhead isn't unknown at this point. In fact, the stock has surged over the last year -- especially since October. Some of that was do to the NVS buyouts in the sector. But, a lot of it was do to ARWR's own wins and progress. But, with plenty of potential and market cap of just $6 billion, Arrowhead could provide more gains in the year ahead -- buyout or not. Amarin (AMRN)Source: Shutterstock A lot has been written about Amarin (NASDAQ:AMRN). The biotech stock has been a roller coaster the last few years, going from obscurity to being on hot lists. The reason comes down to its only medicine -Vascepa.Vascepa is really just a fish oil pill. But man, is it good. Data for the drug was stellar, with patients experiencing a 20% less chance of cardiovascular death, 31% less heart attacks and 28% less strokes. All in all, Vascepa was able to reduce cardiovascular risk by 25%. With its big cache of data and FDA approval, AMRN now has a blockbuster on its hands. Patients facing cardiovascular events who are already on statins now have another line of defense to fight. With that, AMRN now predicts that it'll be able to accumulate $650 to $700 million in sales this year.So, why buyout potential? That's an easy source of bolt-on revenue with some decent growth prospects.Cardiovascular disease remains a huge threat that only continues to get worse as diet and genetics play an increasing role. Vascepa has the potential to be the next Lipitor in that fight. And that blockbuster potential makes it a great add-on for drug companies with big cardiovascular portfolios. With a market cap of only $7 billion, Amarin is a pretty easy pill to swallow for a larger biotech stock looking to boost its sagging growth potential. * 3 Oil Stocks That Are Worth Looking Into Now In the end, Vascepa could be a blockbuster and that could lead to a sale of ARMN stock. Intercept Pharmaceuticals (ICPT)Source: Shutterstock Non-alcoholic SteatoHepatitis (NASH) remains a tough nut to crack. The progressive liver disease can destroy the organ, and is projected to become the leading cause of all liver transplants this year. For nations with fatty diets, prevalence of NASH is estimated to be as much as 20% of the total population. The problem is that most potential treatments for the disease have fallen flat.And, that could make Intercept Pharmaceuticals (NASDAQ:ICPT) the only boat in the sea.Intercept's drug Ocaliva is used to treat a rare, chronic liver disease known as primary biliary cholangitis (PBC). PBC is very similar to NASH. This allowed ICPT to pivot the medicine and results were pretty great. So great, that ICPT recently submitted the drug for review with the FDA.Perhaps even better is that the agency granted Intercept priority review for the drug. That could lead to quicker approval time and reduce the headaches ICPT needs to get the therapy out to market.Given the potential size of NASH and the need for the drug, ICPT could be looking at a major blockbuster on it hands. And as the only man standing in the sector, that could lead to plenty of buyout activity for the stock. This is especially true as shares of the firm have slipped over the last year, but gained traction in October. With a market cap of about $4 billion, Intercept is a very digestible for many other biotech stocks.In the end, ICPT is sitting right in the sweet spot for mergers and acquisitions activity. With strong growth potential, first-mover status and a low market cap all being factors. At the time of writing, Aaron Levitt did not hold a position in any stock mentioned. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The Top 15 Stocks to Buy in 2020 * The 7 Most Important Companies That Didn't Survive the 2010s * 4 Mega-Tech Stocks Reaching for the Sky The post 3 Biotech Stocks to Bank on for Buyouts in 2020 appeared first on InvestorPlace.
- Zacks
The Zacks Analyst Blog Highlights: Novartis, McDonald's, Bristol-Myers Squibb, CME and UBS
The Zacks Analyst Blog Highlights: Novartis, McDonald's, Bristol-Myers Squibb, CME and UBS
- Zacks
Top Analyst Reports for Novartis, McDonald's & Bristol-Myers Squibb
Top Analyst Reports for Novartis, McDonald's & Bristol-Myers Squibb
- GuruFocus.com
Among Top 5 Pharma Companies, Pfizer Was the Worst Performer in 2019
Other members of the top tier rewarded shareholders with solid gains, led by Roche Continue reading...
- American City Business Journals
Cambridge startup bringing AI to drug development raises $60M
A Cambridge startup that helps drugmakers analyze patient and drug information has raised a new financing round valued that's more than five times larger than what it raised just two years ago.
- Investor's Business Daily
Is Biogen Stock A Buy On Renewed Hope In Alzheimer's Disease?
Biogen stock popped in mid-October after the biotech company said a broader analysis showed some promise for its Alzheimer's treatment, aducanumab. Is now the time to buy Biogen stock?
- MarketWatch
Why Bank of America expects the hot European pharmaceuticals sector to stumble — and it’s not a fear of U.S. drug prices
Bank of America expects European stocks broadly to rise this year, but its key underweight call is the pharmaceutical sector, and the recommendation has nothing to do with talk of reining in U.S. drug prices.
- Reuters
Novartis, Merck and Allergan join those raising U.S. drug prices for 2020
Novartis AG, Merck & Co Inc and Allergan Plc were among companies that raised U.S. prices on more than 100 prescription medicines on Friday, bringing the tally to 445 drugs that will cost more in 2020, according to data analyzed by healthcare research firm 3 Axis Advisors. Nearly all of the price increases are below 10%, with the median price increase around 5%, according to 3 Axis. Swiss drugmaker Novartis raised prices on nearly 30 drugs including psoriasis treatment Cosentyx and multiple sclerosis medicine Gilenya, 3 Axis said.
- Zacks
Incyte's (INCY) Itacitinib Fails in Late-Stage GVHD Study
Incyte (INCY) fails to meet goals in the phase III study on itacitinib for the treatment of first-line acute GVHD.
- Zacks
Glaxo (GSK) Shares Continue to Witness Upside: Here's Why
Glaxo's (GSK) successful product launches, increasing focus on the oncology area, and positive pipeline and regulatory updates are driving the stock.
- Zacks
Global Blood (GBT) Shares Double in a Year, Focus on Oxbryta
Shares of Global Blood Therapeutics (GBT) have gained in the past year as its lead candidate voxelotor gets FDA approval for the treatment of SCD in patients aged 12 years or above.
- GuruFocus.com
Novo Nordisk: A Rare Case of Pharma With Balanced Risk and Reward
A strategic focus, dominant positions and secular growth opportunities outweigh the general pipeline risk Continue reading...
- Zacks
3 Biotech Stocks Likely to Maintain Solid Momentum in 2020
With the biotech sector gaining steam in recent times, we shortlist three biotech stocks that are set to maintain momentum in 2020.
- Benzinga
Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus
Biotech stocks advanced in the penultimate week of the year, and the iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) is on track to end the year with gains in excess of 25%. The previous week saw FDA ...
- GlobeNewswire
ROSEN, NATIONAL TRIAL LAWYERS, Continues to Investigate Securities Claims Against Novartis AG – NVS
NEW YORK, Dec. 27, 2019 -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG.
- Insider Monkey
Novartis AG (NVS) vs. Top 20 Hedge Fund Stocks in 2019
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
- Yahoo Finance Video
New antibiotics struggle to generate sales, pharma companies hurt
Pharmaceutical companies struggle to generate sales as doctors prescribe new anti-biotic, resistant superbugs sparingly. Yahoo Finance's On The Move panel break down the latest developments.
